WEBULL
WebtradeDownload

CME Group (CME) After FX Records And Dairy Expansion With Valuation In Focus

Simply Wall St · 2d ago

CME Group (CME) is back in focus after its FX futures and options reached record open interest, and the business agreed to absorb European dairy contracts from the European Energy Exchange.

For context, CME Group shares trade at US$278.23, with recent momentum softening a little after a 1-day share price return that declined 1.09% and a 7-day share price return that fell 2.87%. The 30-day share price return of 5.53% and 90-day share price return of 5.47% hint at interest building around records in FX derivatives and new product launches, while a 1-year total shareholder return of 10.51% and 5-year total shareholder return of 81.76% show that longer term holders have been rewarded despite short term swings.

Scan beyond CME Group and see which exchanges and financial infrastructure stocks are also attracting institutional flow by checking the hand picked 82 resilient stocks with low risk scores today.

FX records, fresh product launches and a US$101.1b market value put CME Group in a strong spot after the recent run. Does that set up an attractive risk reward for new money, or does it mostly protect existing holders?

Most Popular Narrative: 1.5% Undervalued

CME Group’s most followed narrative pegs fair value at about $282.36, only slightly above the last close of $278.23. This puts the spotlight on the fine print behind that call.

New product innovations (e.g., Micro contracts, expansion into crypto, FX Spot+), ongoing tech-driven operating efficiencies (cloud migration and tokenization initiatives), and strengthening of strategic partnerships (such as the long-term NASDAQ index license extension and Google Cloud collaboration) are enhancing operating leverage and EBITDA/net margin performance.

Read the complete narrative.

Investors may want to see what kind of earnings curve and margin profile that product and technology mix is based on. The narrative leans on steady top line expansion, slightly softer profitability, and a future earnings multiple that still assumes investors will pay a premium for CME Group’s cash flow profile.

Result: Fair Value of $282.36 (ABOUT RIGHT)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, CME Group’s story can change quickly if decentralized finance pulls liquidity away from regulated venues, or if lower volatility drags on futures volumes and fees.

Find out about the key risks to this CME Group narrative.

Another View on CME Group’s Valuation

Analysts using a future earnings framework see CME Group as only about 1.5% below their US$282.36 fair value mark, which feels tight. On simple P/E math, though, the story looks different. The stock trades on 23.5x earnings against a fair ratio of 15.7x.

That is a sizeable gap. The multiple also sits below the broader US Capital Markets average of 39.7x and slightly under a 26.1x peer group. This sends a mixed signal about how much safety margin investors might see at today’s price. The key issue is whether that richer than fair ratio reflects resilience or simply leaves less room for error if growth or volumes cool.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:CME P/E Ratio as at Sep 2026
NasdaqGS:CME P/E Ratio as at Sep 2026

Next Steps

Mixed signals around CME Group’s valuation will mean different things to different investors. Move quickly, study the data for yourself, and weigh both the upside and the caution flags in the 2 key rewards and 1 important warning sign.

Looking for more CME Group style investment ideas?

If CME Group has sharpened your focus on quality, do not stop here. Broaden your watchlist with targeted ideas that match your goals and risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.